Orexigen(R) CFO to Resign After Contrave Rejection
About a week after Orexigen® announced cuts of about 40% of their workforce in the aftermath of the FDA's response letter requiring further studies bfore Contrave® could be approved, Graham Cooper, senior vice president, Finance, CFO and treasurer has announced that he will resign.
Cooper, who has been with Orexigen® since 2006, is leaving for personal reasons. He will remain in his current position until the year-end results are in and the annual report has been filed with the Securities and Exchange Commission. Jay Hagan, who is the senior vice president, Corporate Development and Strategy, will take over as the interim CFO.
Orexigen Therapeutics, Inc. (OREX) stock price closed the week at $3.29.
Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion Diet Weight Loss Losing WeightEmpaticFDA
Cooper, who has been with Orexigen® since 2006, is leaving for personal reasons. He will remain in his current position until the year-end results are in and the annual report has been filed with the Securities and Exchange Commission. Jay Hagan, who is the senior vice president, Corporate Development and Strategy, will take over as the interim CFO.
Orexigen Therapeutics, Inc. (OREX) stock price closed the week at $3.29.
Technorati Tags: Contrave™ naltrexone Diet Pills Weight Loss Pillsbupropion Diet Weight Loss Losing WeightEmpaticFDA
Labels: CFO, contrave, diet, diet pill, losing weight, orexigen, weight loss, weight loss pills
posted by Ken MacKenzie @ 4:25 AM
0 Comments:
Post a Comment
<< Home